title: The relationship between introduction of American society of clinical oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospital.
abstract: BACKGROUND
  Clinical practice guidelines are issued periodically by professional medical societies or committees to assist practitioners in clinical decision making. However, it is unclear whether such guidelines have any lasting impact on clinical practice.
  
  
  OBJECTIVE
  The purpose of this study was to assess the impact of the American Society of Clinical Oncology (ASCO) guidelines regarding use of hematopoietic colony-stimulating factors (CSF) on cancer care in a university hospital in Paris.
  
  
  METHODS
  The study was performed at Hĵpital Tenon, an 830-bed university hospital in Paris, in 1996 and 1997, both before and after the ASCO guidelines were implemented. The guidelines were first disseminated as a continuing medical education program and then actively implemented using a CSF prescription order form summarizing the guidelines. This form had to be used during the patient consultation and was sent to the Hĵpital Tenon pharmacy for CSF dispensation. Even if CSF use did not comply with the ASCO guidelines, the pharmacy filled the prescription. Seven other university hospitals in Paris, where the ASCO guidelines were not actively implemented, comprised the control group. The main outcome measure was the proportion of prescriptions in compliance with the 1996 update of the ASCO guidelines. Secondary outcome measures were the proportions of prescriptions in compliance with ASCO guidelines regarding primary prophylactic, secondary prophylactic, and therapeutic CSF administration.
  
  
  RESULTS
  Before implementation of the ASCO guidelines, CSF use in compliance with the guidelines was 39% (41/105) at the study site and 31% (16/51) at the control sites (P > 0.05). Six months after dissemination and implementation of the guidelines, the proportion of CSF prescriptions complying with ASCO guidelines increased significantly versus baseline (P = 0.003) in the study group, to 61% (50/82). However, even after the guidelines were implemented, compliance with guidelines on primary prophylactic CSF administration did not change significantly versus before implementation in the study group (12% [5/41] before implementation vs 6% [2/33] after implementation; P > 0.05).
  
  
  CONCLUSIONS
  The results suggest an association between the active implementation strategy (continuing medical education and CSF prescription reminder form) and physician compliance with the ASCO guidelines. Implementation of the ASCO guidelines appears to have had some impact on medical practice.
authors.affiliation: Service de Pharmacie-Toxicologie, Comité Local du Médicament, Hĵpital Tenon, Paris, France. isabelle.debrix@tnn.ap-hp-paris.fr
authors.forename: I
authors.initials: I
authors.lastname: Debrix
authors.forename: P
authors.initials: P
authors.lastname: Tilleul
authors.forename: B
authors.initials: B
authors.lastname: Milleron
authors.forename: N
authors.initials: N
authors.lastname: Grené
authors.forename: C
authors.initials: C
authors.lastname: Bouleuc
authors.forename: D
authors.initials: D
authors.lastname: Roux
authors.forename: H
authors.initials: H
authors.lastname: Lioté
authors.forename: I
authors.initials: I
authors.lastname: Madelaine
authors.forename: A
authors.initials: A
authors.lastname: Bellanger
authors.forename: O
authors.initials: O
authors.lastname: Conort
authors.forename: J E
authors.initials: JE
authors.lastname: Fontan
authors.forename: F
authors.initials: F
authors.lastname: Le Mercier
authors.forename: C
authors.initials: C
authors.lastname: Bardin
authors.forename: A
authors.initials: A
authors.lastname: Becker
mesh_terms: D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy*; D016522:Oncology Service, Hospital; D010297:Paris; D010348:Patient Care Team; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014481:United States
chemical_list: D003115:Colony-Stimulating Factors